By |

Profile

Chiasma Inc is a biopharmaceutical company which focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. Chiasma offers its products in the United States.

Contact Information

Website: www.chiasmapharma.com
Email: arr@lifesciadvisors.com
Main Phone: +1 617 928-5300
Address: 460 Totten Pond Road
Address 2: Suite 530
State: MA
City / Town: Waltham
Country: USA
Postal Code: 02451

Issuer Information

Exchange: NGS
CEO: Mark J. Fitzpatrick
Employees: 16
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Chiasma Inc is a biopharmaceutical company which focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. Chiasma offers its products in the United States.

Contact Information

Website: www.chiasmapharma.com
Email: arr@lifesciadvisors.com
Main Phone: +1 617 928-5300
Address: 460 Totten Pond Road
Address 2: Suite 530
State: MA
City / Town: Waltham
Country: USA
Postal Code: 02451

Issuer Information

Exchange: NGS
CEO: Mark J. Fitzpatrick
Employees: 16
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 3.77 $ 0.02 (0.53%)
Last Price 3.77 Change $ 0.02 Change % 0.53 Tick N/A
Bid 3.45 Bid Size 1,000.00 Ask 4.90 Ask Size 600.00
Open 3.76 High 3.77 Low 3.52 Prev Close 3.75
Last Trade Volume 68,791 52 Wk Hi 4.87 52 Wk Low 1.20
Market Cap 92.1 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 24,430,643.00 EPS (TTM) -1.21 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 2 10
Number of Buys 1 6
Number of Sells 1 4
Net Activity 0 25000
Last 10 Buys Shares
Scott Minick 1,000
Scott Minick 1,000
Last 10 Sell Shares
Roni Mamluk 1,000
Roni Mamluk 1,000
Roni Mamluk 1,000
Roni Mamluk 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 2.5 2.5 2.5 2.5
Low Target Price Estimate 2.5 2.5 2.5 2.5
Mean Target Price Estimate 2.5 2.5 2.5 2.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 01/17/17 01/17/17 01/17/17 01/17/17
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 1
Mean Rec. 0 0 0 5